Related Experiment Videos
An airway hyperresponsiveness model in rat allergic asthma
1Department of Pharmacology, School of Pharmacy, Hoshi University.
Arerugi = [Allergy]
|February 1, 1993
Summary
Researchers developed a new rat model for allergic asthma, demonstrating significant airway hyperresponsiveness. This response was reduced by leukotriene and thromboxane A2 inhibitors, suggesting key mediators in asthma.
Area of Science:
- Pulmonology
- Allergy and Immunology
- Pharmacology
Background:
- Allergic asthma is characterized by airway hyperresponsiveness (AHR).
- Developing reliable animal models is crucial for understanding asthma pathophysiology.
- Identifying key mediators involved in AHR is essential for targeted therapies.
Purpose of the Study:
- To establish a novel rat model of allergic asthma exhibiting airway hyperresponsiveness.
- To investigate the role of chemical mediators in DNP-Ascaris extract (DNP-Asc)-induced AHR.
- To evaluate the efficacy of specific antagonists in mitigating asthma-related AHR.
Main Methods:
- Male Wistar rats were sensitized with DNP-Asc and challenged via antigen inhalation.
- Airway smooth muscle responsiveness to acetylcholine (ACh) was measured using the Konzett-Rössler method.
- Rats were pretreated with leukotriene antagonist (ONO-1078), thromboxane synthetase inhibitor (ozagrel), and PAF antagonist (CV-3988).
Main Results:
- A significant and marked airway hyperresponsiveness was observed 24 hours post-challenge.
- Pretreatment with ONO-1078 and ozagrel significantly inhibited the increased airway responsiveness.
- CV-3988 showed a tendency to inhibit hyperresponsiveness; airway inflammation was evident.
Conclusions:
- A validated rat model for allergic asthma with significant airway hyperresponsiveness was successfully established.
- Leukotrienes, thromboxane A2, and potentially PAF are identified as key chemical mediators in this asthma model.
- This model provides a platform for further research into asthma mechanisms and therapeutic interventions.